1、1792 ChinaPharmacy 2009Vol.20 No.23S02009 M20 23 *0 =, V。Z_: “50。:0379-63546656。E-mail: ) 0J $ o ) S r4秦 娜*(河南洛阳正骨医院临床药学室, 洛阳市 471000)ms |R969.4DS M AcI|1001-0408(2009)23-1792-03K1目的:比较夫西地酸钠与万古霉素治疗耐甲氧西林金黄色葡萄球菌(MRSA)骨科感染的临床疗效。方法:86例MRSA感染患者随机分为治疗组(46例)与对照组(40例),分别给予夫西地酸钠、万古霉素治疗,均采用静脉滴注给药。记录2组的疗效、细菌清除
2、率及药品不良反应。结果:治疗组与对照组的总有效率分别为91.3 %、92.5%(P 0.05), 细菌清除率分别为87.0%、87.5%(P 0.05)。治疗组无明显不良反应发生,对照组不良反应发生率为7.5%。结论:夫西地酸钠治疗MRSA骨科感染效果与万古霉素相当,且其不良反应较少。1oM夫西地酸钠;耐甲氧西林金黄色葡萄球菌;万古霉素;疗效Clinical Efficacyof SodiumFusidate forOrthopedic Patients Infectedwith Methicillin-resistantStaphy-lococcus AureusQIN Na(Dept.of
3、 Clinical Pharmacy , Henan Luoyang OrthopedicHospital, Luoyang 471000, China)ABSTRACT OBJECTIVE:To evaluate the efficacy of Sodium Fusidate versusvancomycin for orthopedic patientsinfectedwith methicillin-resistant Staphylococcus aureus (MRSA).METHODS:A total of 86 MRSA -infected patients were ran-d
4、omly assigned to receive Sodium Fusidate(trial group, n =46)or vancomycin(control group, n =40)by iv gtt.The clinicalefficacy , bacterialclearance rate, andadverse reactionsof the two groupswere recorded.RESULTS :In the trialgroupversusthe control group, the total effective rate was 91.3%vs.92.5% (P
5、 0.05), the bacterial clearance rate was 87.0%vs.87.5%(P 0.05), and adverse drug reaction wasnone in the trialgroup vs.7.5%of the control group.CONCLUSIONS:Sodium Fusidate is as effective asvancomycin but hasfewer side effects for orthopedic patients infected withMRSA.KEYWORDS Sodium Fusidate;Methic
6、illin-resistant staphylococcus aureus;Vancomycin;EfficacyB vh 。9,M 0 ?1 3, #y , 5 ? M “ Es1T, ?5 V ?0 ? 1n。C-erbB-2 V ? ?5 3? 3xT,V79F ?M V ?, _C-erbB-2VEGF 、MVD V “5 N F4 Z4G 。 ID 1 Tapia C,SavicS,W agner U ,et al .HER-2 gene statusin primary breast cancers and matched distant metas-tasesJ .Breast
7、Cancer Res ,2007,9(3):31. 2 Toi M , Matsumoto T , Bando H.Vascular endothelialgrowth factor :its prognostic,predictive,and therapeu-tic implicationsJ .Lancet Oncol ,2001 ,2(11):667. 3b, g9,等.Galectin-3 VEGF Ki-67MVD M F %M1Vr#ilJ .中国肿瘤临床,2008,35(15):874. 4a!,C, , 等.NF -B 、c-erbB-2VEGF -C FFVr “5M、s
8、W1“J.诊断病理学,2009,16(1):58. 5S,;, 等.5 = 3y0 F 5Vr#ilJ .中国综合临床,2007,23(4):338. 6 TsutsuiS , Kume M , Era S , et al.Prognostic value ofmicrovesseldensity in invasive ductal carcinoma of thebreast J.Breast Cancer ,2003,10(4):312. 7 B W , h bVEGFVr FMVDJ .内蒙古医学院学报, 2009, 31(1):13. 8 Konecny GE, Meng YG ,
9、Untch M , et al.Associationbetween HER-2/neu and vascular endothelial growthfactor expression predicts clinical outcome in primarybreast cancer patientsJ.Clin Cancer Res , 2004,10(5):1 706.( l :2009-04-22 :2009-06-19) $ o ) S nh )B1 。 “v F 3 7? “5, 0J $ o )(MRSA) D M 6 t 2 。 “5D = R , MRSA Kr0。 “MRS
10、A 9F,X?C 00 $ o )3 。yN,s MRSA r0 A, Bt 0 N。 ) BN r F ) F 3 ,MRSA z F )。 MRSA S | zrT,C /。1 ZE1.1h 42007 M8 2008 M8 MR-SA 86 ,h SICU S, sS02009 M20 23 ChinaPharmacy 2009 Vol.20 No.23 1793V2 2F% )_T1 (n)Tab 2 Comparison of bacteriological testresults betweentwogroups(n)FY b“s b“9 b“ b“ q/% F46 40 2 1
11、1 2 87.0vF40 35 2 1 1 1 87.5 FvF。 F46 , 328 , o18 ; M-13 75 a , ( M -(54 20)a;“ 16 , 3 , 7b |i 17 , 5i 2 ,/ i 8 。vF40 , 324 , o16 ; M -16 72 a , ( M -(5611)a;“ 11 , 6 , 7b |i 11 ,m i 9 ,k3 。2FW M -、Y、h#%h1 As。 ) ( V S !s , hs 74,5,A7,?E !s % ), MRSA 。0 kTA U,MRSA - = 、 、v = * S v F )0 3 00,7 ) 。1.2Z
12、E F )(? 0K ) 1 500 mg d -1,820 mg kg -1d-1, 8 h1Q, Q0 HW2 4 h;vF ( 0 ) Q500 mg ,8 Q10 mg kg -1,6 h1Q, Q0 HW 60 min。2F ( 0, G 0 8h f7。1.3 “54S(1)0 -、4i: cB f , 8、 r、 、h1vl、 hs ,.e、? 。(2)0 -、 U?、 / ?_。(3)0 -、“S,% ) !,s k ),i “5s h) 、J 、 、h:、d # 60 E0 k。 H, b“、s b“、9、 、h“5) % ) r,9 % ) b“ q。(4)4 Q? 3,i
13、: cC Q HW,s 01“。1.4 r Sv F )0 “55 4 ,| rs4)。: “5、8、 L i_#h_4 (;A :h f Az, 41; :0h f z, A;r:072 hh f A F。 A 9r,N9 9r q。1.5d9ZE2F1 2_,P 0.05),nV1。V1 2F “5 r1 (n)Tab 1 Comparisonofclinical efficacybetweentwogroups(n)FY A r9r q/ % F46 38 4 2 2 91.3vF40 35 2 2 1 92.52.2% ) r2F (C 00 ),% ) b“ q1 sd9il(P 0
14、.05),nV2。2.3 Q F、 / ? Q? 3。vF1 nQ 015 min H? 3 8, 1 05 dC / ? , 1 02? 3P h|,# HT0、 FV (。3) ) F 3 , 1962 M nQ 0 3,S , X. X FJ 00 $ o )0J .国外医药-抗生素分册,2002,23(1):31. 6 Atkins B, Gottlieb T.Fusidic acid in bone and jointinfectionsJ .Int J Antim -icrob Agents , 1999, 12(Suppl 2):79. 7 Turndge J , Collign
15、onP.Resistence to fusidic acidJ.1794 ChinaPharmacy 2009Vol.20 No.23S02009 M20 23 * D =, V。Z_: = * ?。:0852-8608357。E-mail:#YT: D =。Z_: ? 3。:0852-8608627。E-mail:Int J Antimicrob Agents ,1999 ,12(Suppl 2):35. 8 C,y o,I ,等. 0J $ o )8 F )J .中国药房, 2008, 19(32):2 516. 9B ,fr,u ,等. 08s NJ .中国药房, 2008,19(14)
16、:1 058.10*, V, =. / ? i sJ.中国药房,2003,14(12):741.( l :2008-09-27 :2008-12-22)w o u r1 赵泽驹*,陆 立,罗 旭#(遵义医学院附属医院,遵义市 563003)ms |R969.3;R983DS M AcI|1001-0408(2009)23-1794-02K1目的:探讨曲司氯铵治疗膀胱痉挛的疗效。方法:前列腺增生与膀胱病变术后发生膀胱痉挛的患者86例,随机分为2组,分别用曲司氯铵和盐酸黄酮哌酯治疗至术后1周。比较膀胱痉挛的发生频率、严重程度和不良反应。结果:曲司氯铵控制膀胱痉挛的效果显著优于盐酸黄酮哌酯(P 0.
17、01)。结论:曲司氯铵可有效地抑制经膀胱和膀胱手术后膀胱痉挛的发生。1oM曲司氯铵;膀胱痉挛;手术Efficacyof Trospiumchloride vs.FlavoxateHydrochloride forCystospasmZHAO Ze_ju,LU Li,LUO Xu(The AffiliatedHospital of Zunyi MedicalCollege, Zunyi 563003, China)ABSTRACT OBJECTIVE:To observe the clinical efficacy of Trospiumchloride for cystospasm.METHO
18、DS:86 patientswith cystospasm after undergoing prostatic operation or the operation on bladder were randomly assigned to receive eitherTrospiumchloride or Flavoxate Hydrochloride for 1 week.The incidence and the severity of cystospasm and the adverse drugreaction were compared between the two groups
19、.RESULTS :Trospiumchloride was significantly better than flavoxate hy-drochloride in clinical efficacy for cystospasm(P 0.01).CONCLUSION :Trospiumchloride can effectively inhibit the cys-tospasm in patients undergoing transvesical operation or operation onbladder.KEY WORDS Trospiumchloride;Cystospas
20、m ;Surgery u - F9 3#hM ni?B,? 3 q52% 80%1 。 3y V ? * ?B U O; F r N, _h 。 , - F9 3217 ,* 63 ,? ?46 ; 3274 , o52 ; M -28 76 a, (47.3 a。326 C u86 , Q。 w oF50 , - FK“ 36 , - FM 10 , ?s M“1 ,* M3 。1.2 m Sv “5 2 24 aRh m , 1 f m Z T: - F9 3 U - F M - FK“ T,* U M , ? U ? Ms M“ T。1.3 u l Ci M、 l ,VCul? .e,e m , 4 s; = 6,M 5A8 I , U5, U V UA 。1.4 ZEC u s2F, w oF50 , F36 ,sY w o20 mg ,bid 0.2 g ,bid 1。4 uC q、 HW#0 Q。1.5 “5 N rTsrr。| uC qh 1/2, uC H.e e ? s, u HW 1/2,W# 1 jr。5, jr。1.6d9ZE| 2_,1 2F r Q
